XOMA Royalty Corporation Stock Price, News & Analysis

XOMA Corporation (Nasdaq: XOMA) announced the granting of stock options to its newly appointed Executive Chairman, Owen Hughes, and Chief Investment Officer, Bradley Sitko, as an inducement for their employment. Hughes received options for 175,000 shares with exercise prices of $18.66 and $30.00, vesting in installments throughout 2023. Sitko was granted options for 550,000 shares, with a similar structure. These inducement awards are outside the company's Long Term Incentive Plan and comply with Nasdaq rules. XOMA focuses on acquiring potential future economics associated with therapeutic candidates.

XOMA Corporation (NASDAQ: XOMA) announced leadership changes on January 4, 2023, with Owen Hughes appointed as Executive Chairman and Brad Sitko as Chief Investment Officer. Former CEO Jim Neal has retired, and the Board believes the new structure will support XOMA's growth as a biotech royalty aggregator. Hughes aims to enhance the company's role in the biotech ecosystem, while Sitko will focus on accelerating the royalty aggregation strategy. XOMA currently holds over 70 royalty assets, positioning it for potential cash flow generation.

XOMA Corporation (Nasdaq: XOMA) announced cash dividends for its Series A and Series B Cumulative Preferred Stock. Holders of the Series A stock will receive a dividend of $0.53906 per share, while holders of Series B depositary shares will receive $0.52344 each. These dividends will be paid on January 17, 2023, to shareholders on record as of January 4, 2023. XOMA operates as a biotechnology royalty aggregator, managing a diverse portfolio of over 70 assets related to therapeutic candidates, which it licenses to pharmaceutical companies.

XOMA Corporation has acquired the rights to ebopiprant from ObsEva for $15 million, which includes the Organon License and associated patent estate. The deal allows XOMA to potentially earn up to $475 million in development, regulatory, and sales milestones, plus royalties in the low- to mid-teens upon commercialization. This acquisition marks XOMA's expansion into women's health therapeutics. Ebopiprant has shown promise in reducing preterm labor, with positive results in clinical trials.

XOMA Corporation (Nasdaq: XOMA) announced key financial updates for Q3 2022, reporting total revenues of $0.5 million, down from $0.9 million in Q3 2021. The decline was mainly due to a lack of milestone revenue compared to the previous year. XOMA received its first royalty payment of $0.5 million from Roche related to VABYSMO® sales and also secured $2.5 million from Kuros following Regeneron’s acquisition of Checkmate Pharmaceuticals. The company ended Q3 with $78.3 million cash and no debt, despite a net loss of $4.2 million.

XOMA Corporation (Nasdaq: XOMA) announced cash dividends for its Series A and Series B Cumulative Preferred Stock. Holders of the 8.625% Series A stock will receive $0.53906 per share, while those with the 8.375% Series B stock will receive $0.52344 per depositary share. These dividends are payable on approximately October 17, 2022, to shareholders on record by October 3, 2022. XOMA operates as a biotechnology royalty aggregator, having acquired rights to over 70 assets linked to therapeutic candidates, providing funding to biotechs for their R&D initiatives.

XOMA Corporation will have its CEO, Jim Neal, present at the H.C. Wainwright 24th Annual Global Investment Conference on September 12, 2022, at 10:00 AM ET. The conference aims to highlight XOMA's role as a biotechnology royalty aggregator, helping companies enhance human health by acquiring future economic rights linked to pre-commercial therapeutic candidates. A live stream of the presentation will be accessible here and on XOMA's website. A replay will be available for 90 days post-event.

XOMA Corporation reported its second quarter 2022 financial results, achieving total revenues of $1.0 million, up from $0.9 million in Q2 2021. The net loss widened to $4.7 million compared to $2.2 million in the prior year. Cash at the end of June stood at $83.2 million, with no debt, which management believes will sustain operations for several years. The acquisition of Checkmate Pharmaceuticals resulted in a $2.5 million payment to XOMA, while Rezolute and Day One plan to advance to Phase 3 clinical trials, signaling positive progress in their pipelines.

XOMA Corporation (Nasdaq: XOMA) has announced cash dividends for holders of its Series A and B Cumulative Preferred Stock. Shareholders of the 8.625% Series A stock will receive $0.53906 per share, while holders of the 8.375% Series B stock will receive $0.52344 per depositary share. The dividends are scheduled for payment on July 15, 2022, to shareholders on record by July 1, 2022. XOMA plays a significant role as a biotechnology royalty aggregator, managing over 70 assets related to therapeutic candidates, providing crucial funding for biotech advancement.